Peter Stazzone - 01 Sep 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Chief Financial Officer
Signature: /s/ Peter Stazzone
Issuer symbol: LIXT
Transactions as of: 01 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Sep 2025, 14:58:31 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stazzone Peter	Chief Financial Officer	680 E. COLORADO BLVD., SUITE 180, PASADENA	/s/ Peter Stazzone	02 Sep 2025	0002083297

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+50,000		$0.000000	50,000	01 Sep 2025	Common	50,000	$4.45	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.

Content

Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.